The most common side effects across all these medications are: Gastrointestinal Nausea/vomiting These typically occur when starting treatment or increasing doses, and usually improve within the first few months
The reasons for these differences may be related to the small sample size and the difference in drug intervention dose
The headline finding is encouraging but buried in the subgroup data is a signal that deserves more attention than its been getting

These effects lead to the phosphorylation of L-type calcium channels (LTCC), troponin I (TnI), and phospholamban (PLB), thereby enhancing calcium regulation and cardiac output ( 4.5 NAFLD and CKD Hyperglucagonemia, characterized by elevated plasma glucagon levels, is a well-known feature of various metabolic disorders, including NAFLD and CKD ( 4.5.1 Glucagon in NAFLD Under physiological conditions, glucagon promotes hepatic glycogenolysis, gluconeogenesis, and fatty acid oxidation, while inhibiting de novo lipogenesis through receptor-mediated signaling ( 4.5.2 Glucagon in CKD Glucagon contributes to renal physiology by regulating potassium homeostasis across nephron segments, a function that becomes increasingly relevant in the context of diabetic kidney disease (DKD) ( 5 Discussion Glucagon is now recognized as a systemic hormone implicated in a broad range of metabolic and cardiovascular diseases
Sterility and chain of custody